Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Recruiting now

Conditions studied: HER2-Positive Breast Carcinoma

In brief

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Key facts

Study ID

NCT06557057

Run by

Mayo Clinic

People needed

66

Starts

2023-11-16

Expected to finish

2026-12-01

Last updated by the study team

2026-03-31

Who can join

Age: any. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Post-menopausal women with hormone receptor positive breast cancer, ductal carcinoma in situ (DCIS), or with other high risk breast conditions. Post-menopause will be defined as women who experience 12 months of amenorrhea or have undergone bilateral salpingo-oophorectomy.
• 25 women who are planning to start or are within 6 months of starting treatment with aromatase inhibitors, after consultation in breast clinic and cancer center.
• 25 women who will be starting Tamoxifen (comparative group)
• 25 healthy post menopausal women will also be recruited.

You may not qualify if…

• Established diagnosis of diabetes
• Therapy with medications that could affect glucose metabolism
• Screening fasting glucose ≥ 126 mg/dl, and/or HbA1c ≥ 6.5%
• History of upper GI surgery that alters gastric emptying or causing malabsorption e.g., bariatric surgery, fundoplication

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.